Differential Prognostic Value of Angiography-Derived Microcirculatory Resistance for Coronary Artery Bypass Grafting of Intermediate Coronary Stenosis

Wenlong Yan, MD^{*}; Yangyang Wang, MD^{*}; Haoyu Hu, MSc; Wei Wang, MD; Zhenfu Li, MSc; Xin Zheng, BSc; Sumin Yang, MD

Correspondence to: Sumin Yang, MD, Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China. Email: yangsumin@qdu.edu.cn

* W. Yan and Y. Wang contributed equally.

BACKGROUND: For patients with intermediate coronary stenoses, the prognostic value of coronary artery bypass grafting (CABG) remains controversial. The prognostic impact of CABG may be different according to Murray law-based quantitative flow ratio (µQFR) and angiography-derived microcirculatory resistance (AMR) in patients with intermediate coronary stenoses.

METHODS AND RESULTS Clinical data of 1411 cases who were diagnosed with multivessel coronary artery disease and had coronary artery intermediate stenoses (50% to 70% by visual assessment) between January 2013 and January 2020 were collected. Patients were categorized into CABG and defer groups based on the decision to bypass intermediate stenoses. These patients were further divided into different subgroups based on µOFR and AMR. The primary outcome was the major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of cardiac death, target vessel myocardial infarction, target vessel revascularization and stroke. Multivariable analysis showed AMR (HR = 1.68, 95% CI 1.18-4.14, P = 0.008) was independent factor associated with MACCE in all patients. On receiver-operating characteristic (ROC) curve analysis, the estimated area under the curve was 0.75 (95% CI: 0.72-0.79) for MACCE. Using the maximum Youden's index, the optimal cutoff value for AMR to predict MACCE was 2.50 mmHg*s/cm. In defer group, MACCE was significantly lower in patients with both $\mu QFR > 0.80$ and AMR < 2.50 mmHg*s/cm as compared with patients with μ QFR > 0.80 (13.2% vs 22.0%, P = 0.031) or AMR < 2.50 mmHg*s/cm (13.2% vs 23.6%, P = 0.012) alone. Compared with patients with both normal μ QFR and AMR, patients with both abnormal μ QFR and AMR carried the highest risk for MACCE (HR = 3.46, 95% CI 2.10-5.71, P < 0.001). CABG was associated with a lower risk of MACCE compared with the deferral strategy when both µQFR and AMR were abnormal. In contrast, at normal µQFR and AMR, patients in both CABG and defer groups had similar MACCE outcomes.

CONCLUSIONS: In patients with intermediate coronary stenoses, the prognostic value of treatment strategy differed according to µQFR and AMR, with a significant NOTE this preprint reports new research that has not been certified by peer feview and should stratify risk and muide chinest precision.

treatment strategies for patients with intermediate coronary stenoses.

Key Words: Murray law-based quantitative flow ratio, angiography-derived microcirculatory resistance, coronary artery bypass grafting, intermediate coronary stenosis

Patients with multivessel coronary artery disease experience improved survival rates after undergoing coronary artery bypass grafting (CABG), particularly those with significant comorbidities^{1,2}. The standard practice for this important surgical procedure requires complete revascularization of the coronary artery. However, different studies have different definitions of complete revascularization, so the management of intermediate stenosis is still controversial^{3,4}. Current guidelines recommend coronary physiologic assessment of intermediate stenoses to guide treatment in the absence of documented ischemia^{5,6}. However, unlike the success of coronary physiologic assessment in percutaneous coronary intervention (PCI), it is currently believed that coronary physiologic assessment needs further research in the field of CABG⁶.

Atherosclerotic plaque-induced obstruction causes flow-limiting stenosis in an epicardial coronary artery, which is mechanistically associated with coronary artery disease (CAD). Accumulating studies demonstrate that most patients presenting with myocardial ischemia symptoms have coronary microvascular dysfunction (CMD)⁷⁻¹⁰. CMD affects coronary microvascular structure and/or function and was previously thought to be harmless or not harmful. However, current evidence links CMD to poor quality of life, shortened survival time, and major cardiovascular and cerebrovascular adverse events (MACCE) in CAD patients¹¹⁻¹³. Equipment availability, costs, and the procedure's long duration limit simultaneous invasive physiologic and CMD assessments. The wire- and adenosine-free angiography-derived microcirculatory resistance (AMR) index, is a valid alternative to the index of microcirculatory resistance (IMR) assessment, which is invasive and wire-based. This study assessed the clinical implications of identifying distinct disturbed coronary hemodynamic patterns using Murray law-based quantitative flow ratio (µQFR) and AMR for decision-making regarding coronary revascularization.

METHODS

Study population

Isolated CABG patients at the Affiliated Hospital of Qingdao University from January 2013 to January 2020 were retrospectively analyzed (Fig. 1). The inclusion criteria included: patients diagnosed with multivessel coronary artery disease and had coronary artery intermediate stenoses (50% to 70% by visual assessment). The exclusion criteria included: patients without intermediate stenoses, patients who had left main artery stenosis >50%, image data missing or with poor quality, patients who had emergency surgery, and patients with previous heart surgery. Patients were categorized into CABG and Defer groups based on the decision to bypass intermediate stenoses. The Affiliated Hospital of Qingdao University Institutional Review Board approved the study on October 30, 2023 (QYFY WZLL 28170), and

waived the informed consent requirement.



Figure1 Study flow

Coronary angiography and physiological measurements

The coronary angiography puncture point was the radial or femoral artery, with a 5-F or 6-F sheath diameter, and 100 IU/kg intravenous heparin was used for preoperative anticoagulation. X-ray systems (Allura X per FD20, Philips; Innova IGS520, GE) were used to capture images at \geq 15 frames/s. An expert certified analyst computed the single-view Murray law-based µQFR analysis using the µQFR software (AngioPlus Core, version V3, Shanghai Pulse Medical Technology Inc., Shanghai, China) at CardHemo, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China, an independent academic core laboratory. The single-view µQFR methodology is detailed in a previous study¹⁴.

Study endpoints

Telephone or outpatient follow-up was conducted, and cardiac death, target vessel myocardial infarction or revascularization, and stroke were classified as MACCE. The Academic Research Consortium report¹⁵ guided the clinical outcome classification and patients' hospital records, treating cardiologist, or general practitioner confirmed adverse events.

Statistical analysis

The analysis of normally distributed continuous data involved examining the mean standard deviation (SD) using the Student's t-test, while for non-normally distributed continuous data, the statistical significance of the median and interquartile ranges was

assessed using the Mann-Whitney U test. Categorical variables, expressed as percentages, were examined using Pearson's $\gamma 2$ or Fisher's exact tests. Survival rates for MACCE were computed using the Kaplan-Meier analysis, and the log-rank test was used to assess the differences. Cox proportional regression analysis determined the relationship between AMR and clinical outcomes. The link between the AMR, clinical outcomes, and each variable (Table 2) was evaluated using univariate analyses. Variables with a univariate predictive value of P < 0.10 were included as covariates in the multivariable models (Table 3). The hazard ratio (HR) was estimated at a 95% confidence interval (CI). The area under the curve (AUC) of the receiver-operating characteristic (ROC) curve analysis evaluated AMR's prediction accuracy for MACCE. Youden's index algorithm criterion was used to identify optimal AMR cutoff values. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) analyses were used to adjust for the uneven baseline characteristics of the CABG and Defer groups. After matching, the equilibrium was assessed using standardized mean differences (SMD). Populations were considered well-balanced if the SMD was <10%. The closest neighbor method was used to compute the PSM with a 1:2 ratio and a 0.2 caliper. R Analysis 4.2.2 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) was used for PSM and IPTW assessment. Other statistical analyses and graphics generation were performed using SPSS version 25.0 (IBM, Armonk, NY, USA). P values less than 0.05 was statistically significant.

RESULTS

Baseline characteristics

Figure 1 presents the study's flowchart. Eventually, a total of 1411 patients were included, for coronary artery intermediate stenoses CABG was deferred in 437 patients (Defer group) and performed in 974 patients (CABG group). The study population's key baseline characteristics are summarized in Table 1. About 23.2% of patients were female. The average age of the patients was 60.5 ± 8.4 years, with a BMI was 24.5 ± 3.4 kg/m2. A total of 447 (31.7%) had diabetes, 486 (34.2%) had μ QFR \leq 0.80, the mean AMR was 2.16 \pm 0.82 mmHg*s/cm, and the mean SYNTAX score was 27.0 ± 10.3 . The patients were followed up for a median duration of 5.9 (IQR: 3.9-8.1 years) years.

Table 1. Baseline characteristics of the study population
--

	All patients (n=1411)	CABG group (n=974)	Defer group (n=437)
Age (years)	60.5 ± 8.4	60.2 ± 8.4	61.1 ± 8.6
Female	327 (23.2%)	222 (22.8%)	105 (24.0%)
BMI (kg/m^2)	24.5 ± 3.4	24.5 ± 3.5	24.2 ± 3.2
Hypertension	866 (61.4%)	591 (60.7%)	275 (62.9%)
Diabetes mellitus	447 (31.7%)	302 (31.0%)	145 (33.2%)
PAD	80 (5.7%)	50 (5.1%)	30 (6.9%)
Carotid stenosis	203 (14.4%)	142 (14.6%)	61 (14.0%)
Renal disease	97 (6.9%)	65 (6.7%)	32 (7.3%)
Chronic lung disease	55 (3.9%)	39 (4.0%)	16 (3.7%)
Cerebrovascular disease	38 (2.7%)	25 (2.6%)	13 (3.0%)
Liver Disease	46 (3.3%)	32 (3.3%)	14 (3.2%)
Smoking history	748 (53.0%)	509 (52.3%)	239 (54.7%)

medRxiv preprint doi: https://doi.org/10.1101/2023.11.22.23298932; this version posted November 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Atrial fibrillation or flutter	26 (1.8%) 292 (20 7%)	19 (2.0%)	7 (1.6%)
Prior PCI	191 (13.5%)	134 (13.8%)	57 (13.0%)
LVEF<50%	106 (7.5%)	77 (7.9%)	29 (6.6%)
NYHA class			
Ι	119 (8.4%)	79 (8.1%)	40 (9.2%)
II	678 (48.1%)	475 (48.8%)	203 (46.5%)
III	545 (38.7%)	369 (37.9%)	176 (40.1%)
IV	69 (4.9%)	51 (5.2%)	18 (4.1%)
3-vessel disease	1095 (77.6%)	767 (78.7%)	328 (75.1%)
µQFR≤0.80	483 (34.2%)	356 (36.6%)	127 (29.1%)
AMR (mmHg*s/cm)	2.16 ± 0.82	2.37 ± 0.74	2.01 ± 0.89
SYNTAX	27.0 ± 10.3	27.5 ± 10.6	25.9 ± 9.9

BMI body mass index, PAD peripheral arterial disease, MI myocardial infarction, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, NYHA New York Heart Association, QFR quantitative flow ratio, AMR angiographic microvascular resistance

Predictors of MACCE

Univariate analysis results showed that age, diabetes mellitus, LVEF, μ QFR ≤ 0.80 , AMR, and SYNTAX were relative risk factors for MACCE in all patients (Table 2). Age, diabetes mellitus, renal disease, LVEF, μ QFR \leq 0.80 and AMR were relative risk factors for MACCE in CABG group. Age, diabetes mellitus, carotid stenosis, LVEF, μ QFR \leq 0.80, AMR and SYNTAX were relative risk factors for MACCE in defer group.

In the univariate analysis, variables with P < 0.10 were used in a backward logistic regression analysis. In the multivariable analysis, age (HR = 1.21, 95% CI 1.08-1.69, P = 0.014), diabetes mellitus (HR = 1.41, 95% CI 1.10-2.37, P < 0.001), μ QFR ≤ 0.80 (HR = 1.32, 95% CI 1.07-3.22, P = 0.011) and AMR (HR = 1.68, 95% CI 1.18-4.14, P = 0.008) were independent factors associated with MACCE in all patients (Table 3). Age (HR = 1.77, 95% CI 1.23-2.31, P = 0.017), LVEF (HR = 1.38, 95% CI 1.14-2.87, P = 0.002) and AMR (HR = 1.41, 95% CI 1.23-3.64, P = 0.026) were independently associated with MACCE in the CABG group. Diabetes mellitus (HR = 1.28, 95% CI 1.08-1.53, P = 0.022), μ QFR \leq 0.80 (HR = 2.11, 95% CI 1.04-4.30, P = 0.039) and AMR (HR = 1.64, 95% CI 1.11-3.69, P < 0.001) were independent predictors of MACCE in Defer group.

	All patie	nts	CABG gr	oup	Defer group		
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	
Age	1.51(1.28-2.87)	0.005	1.71(1.29-3.03)	< 0.001	1.02(1.00-1.04)	0.035	
Female	1.33(0.77-2.33)	0.332	1.40(0.90-1.89)	0.068	1.60(0.44-4.85)	0.455	
BMI	1.66(0.44-2.25)	0.568	1.17(0.83-1.51)	0.181	1.05(0.90-1.61)	0.468	
Hypertension	1.26(0.65-2.46)	0.411	1.26(0.95-1.67)	0.118	1.51(0.42-3.24)	0.138	
Diabetes mellitus	1.49(1.15-2.14)	0.020	1.39(1.05-1.84)	0.021	1.74(1.21-2.48)	0.012	
PAD	1.22(0.60-3.19)	0.665	1.60(0.74-2.39)	0.245	1.49(0.49-3.17)	0.478	
Carotid stenosis	1.02(0.97-1.66)	0.268	1.52(0.68-3.15)	0.411	1.43(1.07-2.36)	0.021	
Renal disease	1.78(0.74-4.25)	0.194	1.46(1.12-3.74)	0.025	1.28(0.66-3.81)	0.098	
Chronic lung disease	1.09(0.91-1.33)	0.176	1.14(0.58-4.40)	0.560	1.19(0.41-3.73)	0.322	
Cerebrovascular disease	1.41(0.65-3.07)	0.375	1.08(0.47-3.07)	0.131	1.58(0.53-4.77)	0.478	

 Table 2. Univariate analysis for MACCE

Liver Disease	1.05(0.26-4.32)	0.947	1.27(0.36-4.06)	0.646	1.49(0.56-3.97)	0.416
Smoking history	1.10(0.81-2.55)	0.279	1.32(0.20-4.73)	0.664	1.37(0.57-3.30)	0.471
Atrial fibrillation	1.46(0.45-4.74)	0.527	1.73(0.77-3.91)	0.182	1.10(0.82-2.02)	0.132
Prior MI	1.09(0.92-1.36)	0.176	1.45(0.60-5.98)	0.717	1.41(0.65-3.03)	0.258
Prior PCI	1.10(0.89-1.66)	0.219	1.53(0.77-2.18)	0.118	1.24(0.74-2.08)	0.400
LVEF	1.68(1.13-3.69)	0.006	1.28(1.03-3.39)	0.015	2.36(1.29-4.02)	0.005
NYHA class III IV	1.01(0.96-1.88)	0.132	1.30(0.92-1.71)	0.090	1.32(0.92-1.88)	0.124
3-vessel disease	1.33(0.88-1.99)	0.143	1.22(0.87-1.72)	0.244	2.66(0.93-6.65)	0.170
µQFR≤0.80	1.46(1.09-4.12)	0.005	1.38(1.05-2.81)	0.008	1.63(1.24-2.76)	0.018
AMR	1.79(1.22-4.68)	< 0.001	2.11(1.18-5.87)	0.006	2.54(1.28-3.41)	0.011
SYNTAX	1.29(1.07-3.64)	0.026	1.05(1.03-1.06)	0.165	1.26(1.44-1.98)	< 0.001

BMI body mass index, PAD peripheral arterial disease, MI myocardial infarction, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, NYHA New York Heart Association, µQFR Murray law-based quantitative flow ratio, AMR angiographic microvascular resistance

Table 3.	Multiv	ariable	analysis	for	MACCE
			2		

	All pati	ents	CABG gr	oup	Defer group		
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	
Age	1.21(1.08-1.69)	0.014	1.77(1.23-2.31)	0.017	1.27(0.86-1.88)	0.225	
Female	-	-	1.19(0.76-2.14)	0.363	-	-	
Diabetes mellitus	1.41(1.10-2.37)	< 0.001	1.33(0.52-3.66)	0.521	1.28(1.08-1.53)	0.022	
Carotid stenosis	-	-	-	-	1.10(0.82-1.47)	0.525	
Renal disease	-	-	1.24(0.87-1.69)	0.274	1.06(0.88-1.25)	0.470	
LVEF	1.34(0.73-2.81)	0.364	1.38(1.14-2.87)	0.002	1.76(0.77-3.63)	0.166	
NYHA class III IV	-	-	1.38(0.83-2.11)	0.120	-	-	
µQFR≤0.80	1.31(1.07-3.22)	0.011	1.22(0.79-2.72)	0.203	2.11(1.04-4.30)	0.039	
AMR	1.68(1.18-4.14)	0.008	1.41(1.23-3.64)	0.026	1.64(1.11-3.69)	< 0.001	
SYNTAX	1.19(0.94-1.99)	0.056	-	-	1.53(0.74-3.74)	0.136	

LVEF left ventricular ejection fraction, NYHA New York Heart Association, µQFR Murray law-based quantitative flow ratio, AMR angiographic microvascular resistance

Association between AMR and MACCE

On ROC curve analysis, the estimated AUC was 0.75 (95% CI: 0.72-0.79) for MACCE. AMR's optimal cutoff value for predicting MACCE using Youden's maximum index was 2.50 mmHg*s/cm (Figure 2).



Figure 2 Receiver-Operating Characteristic Curve Analysis

Combined µQFR and AMR strategy

In defer group, we evaluated the predictive value of µQFR combined with AMR for MACCE in 437 patients. Patients with both μ QFR > 0.80 and AMR < 2.50 mmHg*s/cm had significantly lower MACCE incidence than those with μ QFR > 0.80 (13.2% vs 22.0%, P = 0.031) or AMR < 2.50 mmHg*s/cm (13.2% vs 23.6%, P = 0.012) alone (Figure 3).



Figure 3 Stratified Analysis by µQFR and AMR

Medium-term clinical outcomes according to µQFR and AMR in defer group

The Figure 4 depicts the Kaplan-Meier curves for MACCE of 5 years across groups defined by µQFR and AMR in patients in defer group. Compared with patients with both normal µQFR and AMR, patients with both abnormal µQFR and AMR carried the highest risk for MACCE (HR = 3.46, 95% CI 2.10-5.71, P < 0.001). Discordance with normal µQFR and abnormal AMR and discordance with abnormal µQFR and normal AMR led to more MACCE than the group with normal µQFR and AMR (Group B vs Group A: HR = 2.10, 95% CI 1.23-3.59, P = 0.006; Group C vs Group A: HR = 2.43, 95% CI 1.43-4.11, P = 0.001).

Perpetuity. All rights reserved. No reuse allowed without permission.



Figure 4 Clinical Outcomes according to µQFR and AMR in Defer Group

Effect of CABG on medium-term clinical outcomes divided according to μQFR and AMR

In CABG group, patients with μ QFR ≤ 0.80 and AMR ≥ 2.50 mmHg*s/cm were defined as group 1 (n = 144). In defer group, patients with μ QFR ≤ 0.80 and AMR ≥ 2.50 mmHg*s/cm were defined as group 2 (n = 88). The risk of MACCE was lower in group 1 than in group 2 (HR = 0.52, 95% CI 0.33-0.82, P = 0.005, Figure 5A). After PSM and IPTW matching, MACCE remained lower in group 1 than in group 2 (Figure 5B and Figure 5C).

In CABG group, patients with μ QFR > 0.80 and AMR < 2.50 mmHg*s/cm were defined as group 3 (n = 356). In defer group, patients with μ QFR > 0.80 and AMR < 2.50 mmHg*s/cm were defined as group 4 (n = 158). Groups 3 and 4 MACCE did not differ (HR = 1.15, 95% CI 0.73-1.80, P = 0.558, Figure 6A). After PSM and IPTW matching, groups 3 and 4 MACCE did not differ (Figure 6B and Figure 6C).

	Initial Cohort				After PSM				After IPTW			
	Group 1	Group 2	P valve	Group 1	Group 2	P valve	SMD	Group 1	Group 2	P valve	SMD	
	(n=144)	(n=88)		(n=71)	(n=71)			(n=149)	(n=93)			
Age (years)	60.6 ± 8.1	63.3 ± 8.5	0.016	61.2 ± 8.3	62.5 ± 8.4	0.355	0.076	61.1 ± 8.3	61.9 ± 8.5	0.471	0.032	
Female	38 (26.4%)	20 (22.7%)	0.532	17 (23.9%)	15 (21.1%)	0.688	0.022	34 (22.8%)	22 (23.7%)	0.881	0.009	
BMI (kg/m^2)	24.1 ± 3.4	26.3 ± 3.8	< 0.001	24.4 ± 3.5	25.3 ± 3.3	0.117	0.066	24.3 ± 3.5	24.6 ± 3.4	0.513	0.021	
Hypertension	87 (60.4%)	56 (63.6%)	0.625	44 (62.0%)	46 (64.8%)	0.728	0.010	91 (61.1%)	60 (64.5%)	0.591	0.036	
Diabetes mellitus	46 (31.9%)	31 (35.2%)	0.606	21 (29.6%)	24 (33.8%)	0.588	0.054	49 (32.9%)	32 (34.4%)	0.807	0.008	
PAD	7 (4.9%)	7 (8.0%)	0.337	7 (4.9%)	7 (8.0%)	0.337	0.018	7 (4.9%)	7 (8.0%)	0.337	0.025	
Carotid stenosis	20 (13.9%)	9 (10.2%)	0.413	8 (11.3%)	6 (8.5%)	0.573	0.025	21 (14.1%)	9 (10.2%)	0.311	0.033	
Renal disease	8 (5.6%)	7 (8.0%)	0.471	5 (7.0%)	7 (8.0%)	0.546	0.041	10 (6.7%)	7 (8.0%)	0.809	0.014	
Chronic lung disease	8 (5.6%)	3 (3.4%)	0.669	5 (7.0%)	3 (4.2%)	0.716	0.011	8 (5.4%)	6 (6.5%)	0.726	0.039	
Cerebrovascular disease	5 (3.5%)	5 (5.7%)	0.638	3 (4.2%)	4 (5.6%)	1.000	0.000	5 (3.4%)	4 (4.3%)	0.977	0.024	
Liver Disease	4 (2.8%)	4 (4.5%)	0.730	3 (4.2%)	4 (5.6%)	1.000	0.000	6 (4.0%)	4 (4.3%)	0.820	0.020	
Smoking history	73 (50.7%)	53 (60.2%)	0.157	38 (53.5%)	42 (59.2%)	0.499	0.053	85 (57.0%)	54 (58.1%)	0.876	0.011	
Atrial fibrillation or flutter	5 (3.5%)	6 (6.8%)	0.398	4 (5.6%)	5 (7.0%)	1.000	0.000	7 (4.7%)	6 (6.5%)	0.768	0.015	
Prior MI	40 (27.8%)	14 (15.9%)	0.038	16 (22.5%)	13 (18.3%)	0.532	0.038	36 (24.2%)	19 (20.4%)	0.501	0.068	
Prior PCI	25 (17.4%)	11 (12.5%)	0.321	11 (15.5%)	9 (12.7%)	0.630	0.009	25 (16.8%)	13 (14.0%)	0.560	0.061	
LVEF<50%	12 (8.3%)	9 (10.2%)	0.626	6 (8.5%)	8 (11.3%)	0.573	0.065	14 (9.4%)	9 (9.7%)	0.942	0.004	
NYHA class			0.568			1.000	0.000			0.870	0.018	
Ι	20 (13.9%)	14 (15.9%)		9 (12.7%)	10 (14.1%)			24 (16.1%)	13 (14.0%)			
II	70 (48.6%)	36 (40.9%)		35 (49.3%)	31 (43.7%)			66 (44.3%)	39 (41.9%)			
III	45 (31.3%)	34 (38.6%)		22 (31.0%)	26 (36.6%)			50 (33.6%)	36 (38.7%)			
IV	9 (6.3%)	4 (4.5%)		5 (7.0%)	4 (5.6%)			9 (6.0%)	5 (5.4%)			
3-vessel disease	104 (72.2%)	51 (58.0%)	0.025	48 (67.6%)	43 (60.6%)	0.382	0.022	102 (68.5%)	60 (64.5%)	0.526	0.033	
SYNTAX	26.4 ± 10.1	25.1 ± 10.8	0.355	26.2 ± 9.8	25.6 ± 9.6	0.713	0.006	26.2 ± 10.2	25.8 ± 10.5	0.770	0.014	

Table 4. Baseline characteristics of group 1 and 2

BMI body mass index, PAD peripheral arterial disease, MI myocardial infarction, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, NYHA New York Heart Association

	Initial Cohort				After PS	SM		After IPTW			
	Group 3 (n=356)	Group 4 (n=158)	P valve	Group 3 (n=149)	Group 4 (n=149)	P valve	SMD	Group 3 (n=351)	Group 4 (n=162)	P valve	SMD
Age (years)	61.6 ± 8.8	60.7 ± 8.1	0.274	61.1 ± 9.3	60.9 ± 8.3	0.845		61.3 ± 9.2	60.8 ± 8.5	0.558	0.040
Female	72 (20.2%)	45 (28.5%)	0.039	33 (22.1%)	39 (26.2%)	0.417		87 (24.8%)	43 (26.5%)	0.671	0.021
BMI (kg/m^2)	25.6 ± 4.2	24.3 ± 3.8	0.001	25.2 ± 4.1	24.5 ± 3.7	0.123		25.0 ± 4.0	24.6 ± 3.9	0.289	0.077
Hypertension	208 (58.4%)	101 (63.9%)	0.240	88 (59.1%)	95 (63.8%)	0.405		214 (61.0%)	100 (61.7%)	0.870	0.014
Diabetes mellitus	95 (26.7%)	56 (35.4%)	0.044	46 (30.9%)	49 (32.9%)	0.709		108 (30.8%)	55 (34.0%)	0.472	0.055
PAD	23 (6.5%)	7 (4.4%)	0.365	8 (5.4%)	6 (4.0%)	0.584		21 (6.0%)	9 (5.6%)	0.848	0.008
Carotid stenosis	60 (16.9%)	18 (11.4%)	0.111	21 (14.1%)	17 (11.4%)	0.487		52 (14.8%)	19 (11.7%)	0.347	0.024
Renal disease	17 (4.8%)	12 (7.6%)	0.201	8 (5.4%)	10 (6.7%)	0.627		21 (6.0%)	11 (6.8%)	0.725	0.011
Chronic lung disease	16 (4.5%)	6 (3.8%)	0.719	6 (4.0%)	5 (3.4%)	0.759		14 (4.0%)	5 (3.1%)	0.615	0.023
Cerebrovascular disease	11 (3.1%)	8 (5.1%)	0.274	5 (3.4%)	7 (4.7%)	0.556		13 (3.7%)	7 (4.3%)	0.737	0.009
Liver Disease	12 (3.4%)	5 (3.2%)	0.904	5 (3.4%)	4 (2.7%)	1.000		12 (3.4%)	7 (4.3%)	0.615	0.057
Smoking history	215 (60.4%)	79 (50.0%)	0.028	82 (55.0%)	76 (51.0%)	0.486		197 (56.1%)	83 (51.2%)	0.301	0.036
Atrial fibrillation or flutter	8 (2.2%)	5 (3.2%)	0.759	5 (3.4%)	4 (2.7%)	1.000		8 (2.3%)	4 (2.5%)	0.856	0.002
Prior MI	78 (21.9%)	27 (17.1%)	0.211	30 (20.1%)	26 (17.4%)	0.553		75 (21.4%)	31 (19.1%)	0.562	0.029
Prior PCI	45 (12.6%)	14 (8.9%)	0.215	16 (10.7%)	13 (8.7%)	0.558		38 (10.8%)	16 (9.9%)	0.745	0.007
LVEF<50%	28 (7.9%)	5 (3.2%)	0.045	8 (5.4%)	4 (2.7%)	0.239		22 (6.3%)	8 (4.9%)	0.551	0.074
NYHA class			0.518			0.425				0.891	0.001
Ι	39 (11.0%)	12 (7.6%)		14 (9.4%)	10 (6.7%)			35 (10.0%)	13 (8.0%)		
Π	172 (48.3%)	77 (48.7%)		83 (55.7%)	75 (50.3%)			169 (48.1%)	79 (48.8%)		
III	124 (34.8%)	62 (39.2%)		45 (30.2%)	58 (38.9%)			130 (37.0%)	63 (38.9%)		
IV	21 (5.9%)	7 (4.4%)		7 (4.7%)	6 (4.0%)			17 (4.8%)	7 (4.3%)		
3-vessel disease	223 (62.6%)	88 (55.7%)	0.137	90 (60.4%)	84 (56.4%)	0.481		217 (61.8%)	95 (58.6%)	0.493	0.036
SYNTAX	25.3 ± 8.8	23.5 ± 9.2	0.035	25.1 ± 9.1	24.2 ± 9.8	0.313		25.0 ± 9.5	24.6 ± 10.2	0.665	0.021

Table 5. Baseline characteristics of group 3 and 4

BMI body mass index, PAD peripheral arterial disease, MI myocardial infarction, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, NYHA New York Heart Associa



Figure 5 Clinical Outcomes of Group 1 and Group 2 A. Clinical Outcomes in Initial Cohort B. Clinical Outcomes of Patients after PSM C. Clinical Outcomes of Patients after IPTW



Figure 6 Clinical Outcomes of Group 3 and Group 4 A. Clinical Outcomes in Initial Cohort B. Clinical Outcomes of Patients after PSM C. Clinical Outcomes of Patients after IPTW

DISCUSSION

This study assessed the predictive significance of AMR for CABG in intermediate coronary stenosis. The primary outcomes are outlined. First, AMR independently predicted MACCE in the 5-year follow-up of patients who received CABG and those who did not. The optimal cutoff value for AMR to predict MACCE was 2.50 mmHg*s/cm, and the estimated AUC was 0.75. Second, µQFR and AMR assessments in patients with intermediate stenoses offered insights into the microvascular system that were not apparent when reviewing only the clinical or angiographic features. Patients with abnormal AMR and µQFR had worse clinical outcomes than those in other groups. Third, although CABG reduced the risk of MACCE for patients with abnormal μ QFR and AMR, it did not reduce this risk for those with normal μ QFR and AMR.

In ischemia with non-obstructive coronary microvascular disease (INOCA), myocardial ischemia and symptoms are caused by CMD, either alone or in combination with CAD¹⁶. Prior research has demonstrated that in patients without flow-limiting epicardial stenosis, microvascular disease increases the risk of cardiovascular events^{17,18}. Recurrent or persistent angina, even in patients receiving effective PCI or CABG treatment, may be determined in part by CMD. In these cases, angina results from complex, multifactorial, structural, and functional causes¹⁹. However, hyperemic microvascular resistance (HMR) and IMR are rarely used clinically despite CMD's prognostic potential. Their use is limited by cost, procedural time, patient discomfort from intravenous adenosine infusion, and increased procedural risk from manipulating a pressure wire in the infarcted artery. Based on computational flow analysis, several angiography-based solutions against invasive IMR have been proposed and validated for CMD investigation²⁰⁻²². During routine angiographic evaluations, AMR demonstrated its effectiveness as a viable substitute for wire-based IMR measurements in patients with suspected or known CAD^{23} . This study's findings indicated that AMR independently predicted MACCE in all patients. The Youden test indicated that the optimal cutoff value for AMR in the ROC analysis for MACCE was 2.50 mmHg*s/cm, with an estimated AUC of 0.75 (95% CI: 0.72-0.79). This proves that AMR has good predictive value for this group of patients. We also demonstrated that lesions with a baseline AMR > 2.50 mmHg*s/cm showed a higher likelihood of triggering an adverse MACCE event. AMR is easy to measure, which makes it a desirable addition to risk stratification, especially for angiographically stenotic intermediate lesions, which warrant further study.

Further, we found that μ QFR combined with AMR was very good in stratifying the risk in patients with intermediate coronary stenoses who did not receive CABG. The fractional flow reserve (FFR) and µQFR can then be used to guide PCI strategies, as numerous studies have demonstrated the relationship between coronary physiologic

assessment indices and clinical outcomes²⁴⁻²⁶. Based on these insights, it has been suggested that FFR and µQFR could be used to guide target arteries for CABG. Finally, some researchers believe that CABG prolongs life expectancy, and using FFR to direct revascularization is not as logical for CABG as it is for PCI²⁷. Our study explored the guiding value of coronary artery physiologic assessment indices in CABG from a new perspective. For patients with intermediate coronary stenoses who did not receive CABG, those with both normal µQFR and AMR had significantly lower MACCE than those with normal µQFR or AMR alone (Figure 3). Meanwhile, compared with both normal µOFR and AMR (Group A), both abnormal µOFR and AMR (Group D) carried the highest risk for MACCE (Figure 4). After finding this interesting result, we compared the effects of CABG on these different risk groups. For patients with both abnormal µQFR and AMR, MACCE reduced significantly in the CABG group compared to the Defer group. Conversely, for patients with both normal µQFR and AMR, both groups had a similar risk of MACCE. And the results were consistent in the initial patients and patients after PSM or IPTW matching (Figures 5 6). These results demonstrate that in patients with intermediate coronary stenoses, CABG is beneficial in the cohort with both abnormal µQFR and AMR cohort but not in those with normal µQFR and AMR. This may be explained by the improved microvascular resistance in the abnormal µQFR and AMR cohorts due to CABG-induced epicardial coronary stenosis relief, leading to increased myocardial perfusion. Despite the widespread belief that PCI or CABG do not affect microvascular resistance, a previous study demonstrated that after coronary revascularization, increased distal coronary pressure significantly reduced the microvascular resistance index²⁸. Similarly, findings from the current study indicate that combining uOFR with AMR can effectively identify patients with intermediate coronary stenoses who may benefit from CABG and those who could be safely deferred.

Study limitations

First, this study has the inherent drawbacks of a retrospective registry, even with the large sample size and follow-up duration. As a result, a prospective randomized study is required to confirm these conclusions. Second, AMR relies on angiography, image quality, and optimal projection. For this study's AMR analysis, we excluded 4.5% of the patients because the angiographic image was of low quality. Third, selection bias may have occurred because the final decision for CABG was at the operator's discretion. Although the results of the multivariable adjusted analysis were consistent with the PSM and IPTW analysis, it is important to take into account the potential impact of unmeasured bias.

CONCLUSIONS

In the 5-year-follow-up evaluation, AMR independently predicted MACCE in patients with intermediate coronary stenoses. The treatment strategy's prognostic values varied, with significant interaction, based on the µQFR and AMR. CABG was associated with a lower risk of MACCE compared with the deferral strategy when both µQFR and

All rights reserved. No reuse allowed without permission.

AMR were abnormal. In contrast, at normal μ QFR and AMR, patients in both CABG and Defer groups had similar MACCE outcomes. The combination of μ QFR and AMR can help stratify risk and guide treatment strategies for patients with intermediate coronary stenoses.

Affiliations

Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China (W.Y., Y. W., H.Hu., W. W., Z. L., S. Y.); Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China (Y.W.); Department of Operating Room, The Affiliated Hospital of Qingdao University, Qingdao, China (X.Z.).

Sources of Funding None.

Disclosures None.

- Bianco V, Kilic A, Mulukutla S, Gleason TG, Kliner D, Allen CC, Habertheuer A, Aranda-Michel E, Humar R, Navid F, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with reduced ejection fraction. *J Thorac Cardiovasc Surg.* 2021;161. doi: 10.1016/j.jtcvs.2020.06.159
- Holm NR, Mäkikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, Trovik T, Kellerth T, Kalinauskas G, Mogensen LJH, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. *Lancet*. 2020;395:191-199. doi: 10.1016/S0140-6736(19)32972-1
- Gaba P, Gersh BJ, Ali ZA, Moses JW, Stone GW. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. *Nat Rev Cardiol.* 2021;18:155-168. doi: 10.1038/s41569-020-00457-5
- 4. Leviner DB, Torregrossa G, Puskas JD. Incomplete revascularization: what the

surgeon needs to know. *Ann Cardiothorac Surg*. 2018;7:463-469. doi: 10.21037/acs.2018.06.07

- Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019;40. doi: 10.1093/eurheartj/ehy394
- 6. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022;79. doi: 10.1016/j.jacc.2021.09.006
- Ya'qoub L, Elgendy IY, Pepine CJ. Syndrome of Nonobstructive Coronary Artery Diseases: A Comprehensive Overview of Open Artery Ischemia. *Am J Med.* 2021;134:1321-1329. doi: 10.1016/j.amjmed.2021.06.038
- Beltrame JF, Tavella R, Jones D, Zeitz C. Management of ischaemia with non-obstructive coronary arteries (INOCA). *BMJ*. 2021;375:e060602. doi: 10.1136/bmj-2021-060602
- Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, Prescott E, Karam N, Appelman Y, Fraccaro C, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. *Eur Heart J.* 2020;41:3504-3520. doi: 10.1093/eurheartj/ehaa503

- 10. Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, Patel MR, Sandhu A, Valle J, Magid DJ, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA*. 2014;312:1754-1763. doi: 10.1001/jama.2014.14681
- Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, Hainer J, Bibbo CF, Dorbala S, Blankstein R, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J*. 2018;39:840-849. doi: 10.1093/eurheartj/ehx721
- Schumann CL, Mathew RC, Dean J-HL, Yang Y, Balfour PC, Shaw PW, Robinson AA, Salerno M, Kramer CM, Bourque JM. Functional and Economic Impact of INOCA and Influence of Coronary Microvascular Dysfunction. *JACC Cardiovasc Imaging*. 2021;14:1369-1379. doi: 10.1016/j.jcmg.2021.01.041
- Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, Niccoli G, Crea F. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2021;78:1352-1371. doi: 10.1016/j.jacc.2021.07.042
- Tu S, Ding D, Chang Y, Li C, Wijns W, Xu B. Diagnostic accuracy of quantitative flow ratio for assessment of coronary stenosis significance from a single angiographic view: A novel method based on bifurcation fractal law. *Catheter Cardiovasc Interv.* 2021;97 Suppl 2:1040-1047. doi: 10.1002/ccd.29592
- 15. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel M-A, van Es G-A, Zuckerman B, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus

Document. Eur Heart J. 2018;39:2192-2207. doi: 10.1093/eurheartj/ehy223

- Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski JC, Bairey Merz CN. International standardization of diagnostic criteria for microvascular angina. *Int J Cardiol.* 2018;250:16-20. doi: 10.1016/j.ijcard.2017.08.068
- Dhawan SS, Corban MT, Nanjundappa RA, Eshtehardi P, McDaniel MC, Kwarteng CA, Samady H. Coronary microvascular dysfunction is associated with higher frequency of thin-cap fibroatheroma. *Atherosclerosis*. 2012;223:384-388. doi: 10.1016/j.atherosclerosis.2012.05.034
- Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim H-S, Loh JP, Oldroyd KG. Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. *Circulation*. 2013;127:2436-2441. doi: 10.1161/CIRCULATIONAHA.112.000298
- Mangiacapra F, Del Buono MG, Abbate A, Gori T, Barbato E, Montone RA, Crea F, Niccoli G. Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment. *Prog Cardiovasc Dis.* 2020;63:233-242. doi: 10.1016/j.pcad.2020.02.009
- 20. Scarsini R, Shanmuganathan M, Kotronias RA, Terentes-Printzios D, Borlotti A, Langrish JP, Lucking AJ, Ribichini F, Ferreira VM, Channon KM, et al. Angiography-derived index of microcirculatory resistance (IMRangio) as a novel pressure-wire-free tool to assess coronary microvascular dysfunction in acute coronary syndromes and stable coronary artery disease. *Int J Cardiovasc Imaging*. 2021;37:1801-1813. doi: 10.1007/s10554-021-02254-8

- 21. De Maria GL, Scarsini R, Shanmuganathan M, Kotronias RA, Terentes-Printzios D, Borlotti A, Langrish JP, Lucking AJ, Choudhury RP, Kharbanda R, et al. Angiography-derived index of microcirculatory resistance as novel. а pressure-wire-free tool to assess coronary microcirculation in ST elevation myocardial infarction. Int J Cardiovasc Imaging. 2020;36:1395-1406. doi: 10.1007/s10554-020-01831-7
- Tebaldi M, Biscaglia S, Di Girolamo D, Erriquez A, Penzo C, Tumscitz C, Campo G. Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept Study. *J Interv Cardiol.* 2020;2020:8887369. doi: 10.1155/2020/8887369
- 23. Fan Y, Fezzi S, Sun P, Ding N, Li X, Hu X, Wang S, Wijns W, Lu Z, Tu S. In Vivo Validation of a Novel Computational Approach to Assess Microcirculatory Resistance Based on a Single Angiographic View. *J Pers Med.* 2022;12. doi: 10.3390/jpm12111798
- 24. Zimmermann FM, Omerovic E, Fournier S, Kelbæk H, Johnson NP, Rothenbühler M, Xaplanteris P, Abdel-Wahab M, Barbato E, Høfsten DE, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. *Eur Heart J.* 2019;40:180-186. doi: 10.1093/eurheartj/ehy812
- 25. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, Engstrøm T, Kääb S, Dambrink J-H, Rioufol G, et al. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. *N Engl J Med.* 2018;379:250-259. doi:

10.1056/NEJMoa1803538

- 26. Xu B, Tu S, Song L, Jin Z, Yu B, Fu G, Zhou Y, Wang Ja, Chen Y, Pu J, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. *Lancet.* 2021;398:2149-2159. doi: 10.1016/S0140-6736(21)02248-0
- Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. *Lancet.* 2015;386:702-713. doi: 10.1016/S0140-6736(15)61220-X
- Verhoeff B-J, Siebes M, Meuwissen M, Atasever B, Voskuil M, de Winter RJ, Koch KT, Tijssen JGP, Spaan JAE, Piek JJ. Influence of percutaneous coronary intervention on coronary microvascular resistance index. *Circulation*. 2005;111:76-82.